注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Immuron Ltd是一家商业和临床阶段的生物制药公司,专注于多克隆抗体的开发和商业化,以满足未满足的医疗需求。该公司通过两个部门运营:研发(R&D)部门和超免疫产品部门。研发部门专注于在澳大利亚、以色列和美国进行的研发项目。超免疫产品部门在澳大利亚、美国和加拿大从事Travelan和Protectyn产品活动。该公司的旗舰产品包括Travelan和Protectyn。Travelan是一种获得许可的天然保健产品,用于降低旅行者腹泻的风险。Travelan是一种非处方免疫补充剂,可用于降低腹泻风险并减轻轻微胃肠道疾病的症状。Protectyn产品有助于促进消化和健康的胃肠系统健康;支持和维持健康的肝功能,增强免疫防御。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Daniel Pollock | 63 | 2012 | Independent Non-Executive Director |
Glenn S. Tillotson | - | - | Member of Advisory Board |
Miriam Vos | - | - | Member of Advisory Board |
Arun J. Sanyal | - | - | Member of Advisory Board |
Dena Lyras | - | - | Member of Advisory Board |
Stephen Anastasiou | 66 | 2013 | Independent Non-Executive Director |
Teena Chopra | - | - | Member of Advisory Board |
Ravi Savarirayan | 56 | 2017 | Independent Non-Executive Director |
Gerhard Rogler | - | - | Member of Advisory Board |
Stephen A. Harrison | - | - | Member of Advisory Board |
Paul Feuerstadt | - | - | Member of Advisory Board |
Sahil Khanna | - | - | Member of Advisory Board |
Manal Abdelmalek | - | - | Member of Advisory Board |
Roger Aston | 67 | 2012 | Independent Non-Executive Director |
Paul Brennan | 62 | 2022 | Independent Non-Executive Chairman |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核